Chemotherapy of respiratory syncytial virus infections: the final breakthrough.

Abstract

Respiratory syncytial virus (RSV) infection is the leading cause of hospitalisation for children under 5 years of age and causes excess mortality in the elderly. There is still no approved vaccine available, although the disease can be curtailed by RSV-specific monoclonal antibody. The only antiviral drug approved for the treatment of RSV infection is ribavirin aerosol, but this treatment is cumbersome and its efficacy is questionable. A new antiviral, GS-5806, which interferes with virus-cell fusion, has proven efficacious in experimental RSV infections in adults.

• Authors: Erik De Clercq
• Journal: International journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 45 Issue 3 Pg. 234-7 (Mar 2015) ISSN: 1872-7913 [Electronic] Netherlands
• PMID: 25684638 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Chemical References

• Antiviral Agents
• Indazoles
• Pyrazoles
• Sulfonamides
• Ribavirin
• presatovir

Topics

• Administration, Inhalation
• Antiviral Agents (therapeutic use)
• Humans
• Indazoles
• Pyrazoles (therapeutic use)
• Respiratory Syncytial Virus Infections (drug therapy)
• Ribavirin (therapeutic use)
• Sulfonamides (therapeutic use)
• Treatment Outcome